CPT 81434 Reimbursement & Benchmarks | OpenPayer

Summary & Overview

CPT 81434: Hereditary Breast Cancer Genomic Sequence Analysis Panel

CPT code 81434 represents a comprehensive genetic testing panel for hereditary breast cancer-related disorders, including sequencing of at least 14 key genes associated with increased cancer risk. This code is significant nationally as it supports early identification of genetic susceptibility, enabling informed clinical management for patients with a family history or risk factors for breast and ovarian cancer. The procedure is typically performed in a laboratory setting and is recognized by major payers such as Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare.

Readers will gain insight into payer coverage policies, clinical benchmarks, and recent policy updates relevant to genetic testing for hereditary breast cancer. The publication also provides context on the clinical importance of this testing, including its role in guiding preventive strategies and treatment decisions. Key modifiers, associated taxonomies, and related CPT codes are discussed to help stakeholders understand billing nuances and the broader landscape of genetic testing services. This summary offers a clear overview of the code's clinical and policy relevance, supporting healthcare professionals, administrators, and policy analysts in navigating the evolving field of hereditary cancer testing.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareCPT 81434genetic testinghereditary breast cancerlaboratory servicesclinical geneticspolicy updatesbenchmarksmedical billingoncologygenomic sequence analysis

CPT Code Overview

CPT code 81434 is used for genetic testing related to hereditary breast cancer disorders. This code covers a genomic sequence analysis panel that must include sequencing of at least 14 genes, such as ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, STK11, and TP53. The typical site of service for this procedure is a laboratory setting (POS 81). This test is essential for identifying genetic susceptibility to breast and ovarian cancer, supporting clinical decision-making for patients with a family history or risk factors for these conditions.

Clinical & Coding Specifications

Clinical Context

A patient with a personal or family history of breast or ovarian cancer is referred for genetic testing to assess hereditary risk. The ordering provider, often a medical geneticist or oncologist, requests a comprehensive genomic sequence analysis panel to evaluate mutations in at least 14 genes associated with hereditary breast cancer-related disorders. The specimen is collected and sent to a laboratory (Place of Service 81) specializing in genetic testing. Results inform clinical management, risk assessment, and potential preventive strategies for the patient and their relatives.

Coding Specifications

Modifiers:
- Modifier 26: Used when reporting only the professional component of the genetic testing service, such as interpretation of results by a qualified provider.
- Modifier 59: Indicates a distinct procedural service, used when the genetic testing is performed separately from other procedures.
Provider Taxonomies:

Taxonomy Code Specialty Name

National Reimbursement Benchmarks

National mean rates for CPT code 81434 among commercial payers (BUCA average: $469.24) are substantially higher than typical Medicare rates, which are not available in the input for comparison. Blue Cross Blue Shield ($502.43) and Cigna ($486.62) have the highest mean rates among the major commercial payers, while Aetna ($437.43) is the lowest.

Rate dispersion varies significantly across payers. Cigna exhibits the widest spread, with a difference of $495.00 between its 75th and 25th percentiles ($682.00 - $187.00), indicating substantial variability in contracted rates. Blue Cross Blue Shield also shows a broad range ($199.33), while Aetna ($199.00) and BUCA ($251.50) are somewhat tighter. UnitedHealth Group has a moderate spread of $291.26. The table and chart below present the full breakdown of national benchmarks for each payer.

81469 – Hereditary breast cancer-related disorders (e.g., hereditary breast and ovarian cancer, hereditary breast cancer-related disorders), genomic sequence analysis panel, must include sequencing of at least 14 genes (e.g., ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, STK11, and TP53)

81456-GENOMIC-SEQUENCE-ANALYSIS-PANEL-EG-TUMOR-OR-BONE-MARROW-RNA

81456 – Genomic sequence analysis panel (e.g., tumor or bone marrow), RNA alterations, 51 or more genes

81416-CYP2C19-CYTOCHROME-P450-FAMILY-2-SUBFAMILY-C-POLYPEPTIDE-19

81416 – CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (e.g., drug metabolism), gene analysis, common variants (e.g., *2, *3, *4, *5, *6, *7, *8, *17)

81411-APOLIPOPROTEIN-E-APOE-GENE-ANALYSIS-COMMON-VARIANTS-EG-E2

81411 – Apolipoprotein E (ApoE) gene analysis, common variants (e.g., *E2, *E3, *E4*)

81477-MOLECULAR-PATHOLOGY-PROCEDURE-LEVEL-9-EG-ANALYSIS-OF-1125

CPT 81477: Molecular Pathology Procedure, Level 9 DNA Sequence Analysis

81410-GENOMIC-SEQUENCING-PROCEDURE-HERITABLE-THORACIC-AORTIC

CPT 81410: Genomic Sequencing for Heritable Thoracic Aortic Disease

81408-TIER-2-MOLECULAR-PATHOLOGY-PROCEDURES-LEVEL

CPT 81408: Advanced Molecular Pathology Laboratory Procedure

81429-GENOMIC-SEQUENCE-ANALYSIS-PANEL-SOLID-ORGAN-NEOPLASM-DNA

CPT 81429: Genomic Sequence Analysis Panel for Solid Organ Neoplasms

81438-HEREDITARY-NEUROENDOCRINE-TUMOR-DISORDERS

CPT 81438: Genomic Sequencing for Hereditary Neuroendocrine Tumor Disorders